Intellia Therapeutics Inc (OQ:NTLA)

Business Focus: Biotechnology & Medical Research

Nov 11, 2020 07:30 am ET
Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments
Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that it has received a grant from the Bill & Melinda Gates Foundation to research in vivo sickle cell disease (SCD) treatments using its CRISPR/Cas9 genome editing technology. This pilot...
Nov 09, 2020 07:30 am ET
Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis
Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that the first patient has been treated with NTLA-2001, which the company is developing as a single-course, potentially curative therapy for transthyretin amyloidosis (ATTR). Intellia’s global...
Nov 05, 2020 07:30 am ET
Intellia Therapeutics Announces Third Quarter 2020 Financial Results
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported operational highlights and financial results for the third...
Oct 29, 2020 07:30 am ET
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its third quarter 2020 financial results and operational...
Oct 19, 2020 07:30 am ET
Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)
Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate its Phase 1 study, which will evaluate...
Oct 07, 2020 04:20 pm ET
Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology
Today, Jennifer Doudna, Ph.D., one of Intellia Therapeutics, Inc.’s scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry for the development of the CRISPR/Cas9 genome editing technology. Dr. Doudna shared the award with her...
Oct 05, 2020 07:30 am ET
Intellia Therapeutics Names John F. Crowley to Board of Directors
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, has appointed John F. Crowley to its Board of Directors. Mr. Crowley is a...
Sep 29, 2020 08:20 am ET
Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is presenting new data demonstrating the persistence of in vivo CRISPR/Cas9 edits to either reduce a disease-causing protein or restore a functional protein, in a mouse model of accelerated liver...
Sep 28, 2020 08:00 am ET
Intellia Therapeutics to Present at Chardan’s Virtual 4th Annual Genetic Medicines Conference
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at Chardan’s Virtual 4th Annual Genetic Medicines Conference...
Sep 02, 2020 08:00 am ET
Intellia Therapeutics to Present at Baird’s 2020 Virtual Global Healthcare Conference
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at Baird’s 2020 Virtual Global Healthcare Conference on...
Aug 06, 2020 07:30 am ET
Intellia Therapeutics Announces Second Quarter 2020 Financial Results
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported operational highlights and financial results for the...
Aug 03, 2020 08:00 am ET
Intellia Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on...
Jul 30, 2020 07:30 am ET
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2020 Earnings and Company Updates
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its second quarter 2020 financial results and operational...
Jun 05, 2020 04:01 pm ET
Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the closing of an underwritten public offering of...
Jun 02, 2020 09:00 pm ET
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today the pricing of an underwritten public offering of...
Jun 01, 2020 04:00 pm ET
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that it has commenced an underwritten public offering of...
Jun 01, 2020 07:00 am ET
Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., June 1, 2020 /PRNewswire/ --...
May 12, 2020 06:00 am ET
Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, is presenting three oral presentations and two poster presentations at...
May 07, 2020 07:30 am ET
Intellia Therapeutics Announces First Quarter 2020 Financial Results
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported operational highlights and financial results for the first...
Apr 30, 2020 07:50 am ET
Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer
Intellia Therapeutics, Inc. (NASDAQ:NTLA) has named David Lebwohl, M.D., as its new executive vice president and chief medical officer. Dr. Lebwohl brings decades of biopharmaceutial leadership and drug development experience, and joins Intellia to...
Apr 30, 2020 07:30 am ET
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its first quarter 2020 financial results and operational...
Apr 28, 2020 04:30 pm ET
Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that five abstracts were accepted for the 23rd Annual Meeting...
Mar 31, 2020 07:30 am ET
FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that the U.S. Food and Drug Administration (FDA) has accepted...
Feb 27, 2020 07:30 am ET
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported operational highlights and financial results for the...
Feb 20, 2020 07:30 am ET
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2019 Earnings and Company Update
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present fourth quarter and full-year 2019 financial results and...
Feb 10, 2020 07:30 am ET
Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, is presenting new data from two of its development programs at Keystone...
Jan 09, 2020 07:30 am ET
Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones
Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today provided an update on recent progress and the Company’s...
Nov 26, 2019 08:00 am ET
Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the Evercore ISI 2nd Annual HealthCONx Conference on...
Oct 31, 2019 07:30 am ET
Intellia Therapeutics Announces Third Quarter 2019 Financial Results
Intellia Therapeutics, Inc. (NASDAQ:NTLA), reported operational highlights and financial results for the third quarter ended September 30, 2019. “In 2019, we continued to leverage the breadth of our genome editing platform to advance our in vivo...
Oct 24, 2019 08:00 am ET
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2019 Earnings and Company Update
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present third quarter 2019 results and operational highlights in a...
Oct 24, 2019 07:30 am ET
Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)
Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology is presenting one oral presentation and four poster presentations at the 27th Annual...
Oct 16, 2019 08:00 am ET
Intellia Therapeutics Announces Presentations at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)
Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced one oral presentation and four poster presentations...
Sep 30, 2019 08:00 am ET
Intellia Therapeutics to Present at October Healthcare Investor Conferences
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the following upcoming healthcare conferences in October:...
Sep 26, 2019 04:30 pm ET
Arbitration Decision Affirms Intellia Therapeutics’ Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 Technology
Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced today that an arbitration panel issued an Interim Award confirming that certain structural and chemical guide RNA modification technologies were exclusively licensed to Intellia by Caribou...
Aug 01, 2019 07:30 am ET
 Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update
Intellia Therapeutics, Inc. (NASDAQ:NTLA), reported operational highlights and financial results for the second quarter ended June 30, 2019. “We continue to build our in vivo and engineered cell therapy pipeline in support of our mission to...
Jul 30, 2019 08:00 am ET
Intellia Therapeutics to Present at August Healthcare Investor Conference
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the following upcoming healthcare conference in August:...
Jul 25, 2019 07:30 am ET
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company Update
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present second quarter 2019 results and operational highlights in a...
May 30, 2019 04:30 pm ET
Intellia Therapeutics to Participate at June Healthcare Investor Conferences
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will participate in the following upcoming healthcare conferences in...
May 28, 2019 07:50 am ET
Intellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer
Intellia Therapeutics, Inc., (NASDAQ:NTLA) has named Laura Sepp-Lorenzino, Ph.D., as its new executive vice president and chief scientific officer. Dr. Sepp-Lorenzino brings decades of leadership and research and development experience, and joins...
May 02, 2019 07:30 am ET
Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update
Intellia Therapeutics, Inc. (NASDAQ:NTLA), reported operational highlights and financial results for the first quarter ended March 31, 2019. Additionally, the Company highlighted important corporate milestones for 2019.       “2019 is off to a...
Apr 29, 2019 07:30 am ET
Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy
Intellia Therapeutics, Inc. (NASDAQ:NTLA), will present today new data, including the first demonstration of targeted gene insertion with CRISPR/Cas9 in the liver of non-human primates (NHPs), at the 22nd Annual Meeting of the American Society of...
Apr 25, 2019 07:30 am ET
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company Update
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present first quarter 2019 results and operational highlights in a...
Apr 15, 2019 04:30 pm ET
Intellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy
Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced three oral presentations at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place April 29-May 2, 2019, in Washington, D.C. Intellia’s data includes...
Feb 27, 2019 06:30 am ET
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
Intellia Therapeutics, Inc.® (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology in both in vivo and ex vivo applications, today reported operational highlights and financial...
Feb 06, 2019 07:50 am ET
Research Report Identifies Norfolk Southern, DENTSPLY SIRONA, Healthcare Realty Trust, PTC, Intellia Therapeutics, and El Paso Electric with Renewed Outlook — Fundamental Analysis, Calculating Forward
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Norfolk Southern Corporation (NYSE:NSC), DENTSPLY SIRONA Inc....
Jan 24, 2019 07:00 am ET
Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, has appointed Fred Cohen, M.D., D.Phil, F.A.C.P., to its board of...
Dec 17, 2018 07:25 am ET
New Research: Key Drivers of Growth for Ashland Global, Intellia Therapeutics, Thor Industries, Zogenix, BWX Technologies, and Heidrick & Struggles International — Factors of Influence, Major Initiati
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ashland Global Holdings Inc. (NYSE:ASH), Intellia Therapeutics, Inc....
Dec 06, 2018 07:30 am ET
Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced an expansion of its existing cell therapy collaboration with...
Nov 08, 2018 04:30 pm ET
Intellia Therapeutics to Present at November Healthcare Investor Conferences
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will participate in the following upcoming healthcare conferences in...
Nov 07, 2018 07:35 am ET
Consolidated Research: 2018 Summary Expectations for STORE Capital, Ares Commercial Real Estate, Intellia Therapeutics, City Office REIT, RealPage, and Data I/O — Fundamental Analysis, Key Performance
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of STORE Capital Corporation (NYSE:STOR), Ares Commercial Real Estate...
Oct 31, 2018 07:30 am ET
Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced financial results and operational developments for the third...
Oct 30, 2018 04:30 pm ET
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate Developments
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present third quarter 2018 results and corporate developments in a...
Oct 29, 2018 04:30 pm ET
Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, has named Glenn Goddard its executive vice president and chief financial...
Oct 18, 2018 08:30 am ET
Intellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell Therapy
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, presented new data from three of its programs, including the company’s...
Oct 10, 2018 08:10 am ET
Analysis: Positioning to Benefit within Big 5 Sporting Goods, Intellia Therapeutics, IDEX, Dolby Laboratories, Quotient Technology, and Modine Manufacturing — Research Highlights Growth, Revenue, and
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Big 5 Sporting Goods Corporation (NASDAQ:BGFV), Intellia Therapeutics,...
Sep 24, 2018 08:30 am ET
Intellia Therapeutics to Present at October Healthcare Investor Conferences
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate in the following upcoming healthcare conferences in October: Monday,...
Sep 10, 2018 04:30 pm ET
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Re
CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Caribou Biosciences, Inc. announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) affirmed the decision by the U.S. Patent and...
Aug 27, 2018 08:00 am ET
Intellia Therapeutics to Present at September Healthcare Investor Conferences
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate in the following upcoming healthcare conferences in September:...
Aug 23, 2018 04:01 pm ET
Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, presented data from studies demonstrating a decrease in amyloid deposition in multiple tissues of...
Aug 23, 2018 08:30 am ET
Intellia Therapeutics to Host Educational Briefing Webinar on Interference Proceedings Relating to CRISPR/Cas9 Genome Editing Technology Patents
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, will host an educational briefing session for investors addressing the interference proceedings...
Aug 06, 2018 07:25 am ET
Detailed Research: Economic Perspectives on IQVIA, Intellia Therapeutics, Deluxe, Superior Industries International, The Navigators Group, and CAI International — What Drives Growth in Today's Competi
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of IQVIA Holdings Inc. (NYSE:IQV), Intellia Therapeutics, Inc. (NASDAQ:NTLA),...
Aug 01, 2018 07:30 am ET
Intellia Therapeutics Announces Second Quarter 2018 Financial Results
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, announced financial results and operational progress for the second quarter of 2018. “In the...
Jun 19, 2018 09:05 am ET
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing
CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), and Caribou Biosciences, Inc., announced that The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier, Ph.D. (collectively,...
May 17, 2018 07:30 am ET
Intellia Therapeutics Announces WT1 as Its First Cell Therapy Target, Following Presentation of Early Data at the American Society of Gene and Cell Therapy 21st Annual Meeting
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, and its research collaborator, Ospedale San Raffaele (OSR), presented at the 21st Annual Meeting...
May 15, 2018 10:56 am ET
New Scientific Advisors Focused on Cell Therapy in Immuno-Oncology and Autoimmunity Join Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, announced new scientific advisors in immuno-oncology and autoimmunity. The advisors hail from...
May 14, 2018 07:30 am ET
New Scientific Advisors Focused on Cell Therapy in Immuno-Oncology and Autoimmunity Join Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, announced new scientific advisors in immuno-oncology and autoimmunity. The advisors hail from...
May 01, 2018 07:30 am ET
Intellia Therapeutics Announces First Quarter 2018 Financial Results
CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, announced financial results and operational progress for the first quarter of...
Apr 25, 2018 07:45 am ET
Consolidated Research: 2018 Summary Expectations for Caseys General Stores, EQT Midstream Partners, LP, Intellia Therapeutics, Blue Buffalo Pet Products, Life Storage, and Thor Industries — Fundamenta
NEW YORK, April 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Caseys General Stores, Inc. (NASDAQ:CASY), EQT...
Apr 23, 2018 08:30 am ET
Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell Therapy 21st Annual Meeting
CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, announced that two scientific abstracts have been accepted for presentation at...
Mar 14, 2018 07:30 am ET
Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR technology, announced financial results and operational progress for the fourth quarter and full year...
Feb 28, 2018 04:30 pm ET
Intellia Therapeutics to Present at March Healthcare Investor Conferences
CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate at the following upcoming healthcare conferences in March:
Feb 27, 2018 09:28 am ET
Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology
CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company developing curative therapeutics using CRISPR/Cas9 technology, announced that Cell Reports will publish at noon ET today its manuscript, “A single administration...
Feb 26, 2018 08:25 am ET
Report: Developing Opportunities within St. Joe, Stone Energy, TravelCenters of America, Intellia Therapeutics, United Community Banks, and Restoration Robotics — Future Expectations, Projections Movi
NEW YORK, Feb. 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of St. Joe Company (NYSE:JOE), Stone Energy...
Jan 31, 2018 04:30 pm ET
Intellia Therapeutics to Present at February Healthcare Investor Conferences
CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present or host one-on-one meetings at the following upcoming healthcare...
Dec 20, 2017 07:40 am ET
Analysis: Positioning to Benefit within Intellia Therapeutics, United Community Banks, CytomX Therapeutics, First Interstate BancSystem, Global Net Lease, and Enable Midstream Partners — Research High
NEW YORK, Dec. 20, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Intellia Therapeutics, Inc. (NASDAQ:NTLA), United Community...
Dec 18, 2017 07:30 am ET
Intellia Therapeutics Names John Leonard, M.D., President and Chief Executive Officer
CAMBRIDGE, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, has named John Leonard, M.D., President and Chief Executive Officer (CEO), effective January 1,...
Dec 11, 2017 07:00 am ET
Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology Meeting
ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using the CRISPR technology, and its collaborator, Novartis, presented initial data from their research...
Nov 02, 2017 04:30 pm ET
Intellia Therapeutics to Present at November Healthcare Investor Conferences
CAMBRIDGE, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare conferences in November:...
Nov 02, 2017 04:30 pm ET
Intellia Therapeutics to Present at November Healthcare Investor Conferences
CAMBRIDGE, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare conferences in November:
Nov 01, 2017 09:00 pm ET
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of an underwritten public offering of...
Nov 01, 2017 07:00 am ET
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced that it has commenced an underwritten public offering...
Oct 30, 2017 04:35 pm ET
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2017 Earnings
CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present third quarter 2017 results to investors and analysts in a conference call on October 31, 2017 at 8:30am EDT, hosted by Nessan Bermingham, Ph.D., Chief Executive Officer and Founder, John Leonard, M.D., Executive Vice President, R&D, and Graeme Bell, Chief Financial Officer. The analyst and investor presentation can be downloaded starting at 8:00am EDT from the Investor...
Oct 03, 2017 04:35 pm ET
Intellia Therapeutics to Present at October Healthcare Investor Conferences
CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare conferences in October:...
Sep 07, 2017 05:00 pm ET
Intellia Therapeutics to Present at Upcoming September Investor Healthcare Conferences
CAMBRIDGE, Mass., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at key September investor healthcare conferences. The Company also has appointed Lindsey Trickett as Vice President of Investor Relations....
Aug 22, 2017 10:31 am ET
Investors: Covered-call reports for Box, Foot Locker, Fabrinet, Intellia Therapeutics and Tenet Healthcare
CHICAGO, Aug. 22, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BOX, FL, FN, NTLA, and THC....
Jul 25, 2017 05:00 pm ET
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing
Appeal seeks reversal of Patent Trial and Appeal Board decision terminating interference without determining priority of inventorship of CRISPR/Cas9 gene editingBrief asserts that the Board failed to properly apply controlling U.S. Supreme Court and Federal Circuit precedents, and ignored evidence of multiple groups readily applying CRISPR/Cas9 gene editing to eukaryotic cells following teachings of Charpentier-Doudna team ZUG, Switzerland, CAMBRIDGE, Mass., BERKELEY, Calif. and DUBLIN, Ireland, July 25, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc...
Jul 24, 2017 06:30 pm ET
Intellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science and Technology Committee
CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technology, announced today the appointment of Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to its Board of Directors. Drs. Slaoui and Verwiel will begin Board responsibilities effective immediately. Intellia’s Board of Directors also is establishing a Science and Technology Committee, which will be chaired by Dr. Slaoui. Additionally, Carl L. Gordon, Ph.D., CFA, General Partner, OrbiMed Ad...
May 13, 2017 08:40 am ET
Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual Meeting
First-time data validates high levels of gene editing and reduction in serum transthyretin protein levels in rat modelsFirst to demonstrate single-dose, in vivo results using proprietary lipid nanoparticle delivery system in mice showing: approximately 97 percent reduction in serum transthyretin protein levels; 70 percent liver editing efficiency following a single dose; six months post-single-dose durability of stable liver editing WASHINGTON, May 13, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potenti...
Mar 01, 2017 07:10 am ET
Intellia Therapeutics to Present at March Investor Healthcare Conferences
CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that company senior leaders will present at key March investor healthcare conferences, including the Cowen and Company 37th Annual Health Care Conference, the Goldman Sachs Third Annual Innovation Symposium, and the Oppenheimer 27th Annual Healthcare Conference....
Feb 15, 2017 06:40 pm ET
Intellia Therapeutics to Hold Conference Call to Address Patent Interference Proceedings
CAMBRIDGE, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA) will hold a conference call with investors on Thursday, February 16, 2017 at 8 a.m., EST. Investors are invited to dial into the conference call hosted by Nessan Bermingham, Ph.D., chief executive officer and founder, Jose E. Rivera, executive vice president and general counsel, and Graeme Bell, chief financial officer....
Feb 15, 2017 03:18 pm ET
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.
UC’s patent application covering the use of CRISPR/Cas9 genome editing technology with a single-guide RNA format in any non-cellular or cellular setting, including human and other eukaryotic cells, will be released from the interference absent an appeal, and may then be prosecuted to potential issuanceAdditional legal channels are available to recognize the priority of the University of California/University of Vienna/Charpentier intellectual property covering eukaryotic cellsU.S. Patent Trial & Appeal Board did not make a determination regarding which party in the interference is the firs...
Feb 01, 2017 04:05 pm ET
Intellia Therapeutics to Present at Leerink Partners 6th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Executive Officer and Founder Nessan Bermingham, Ph.D., will present at the Leerink Partners 6th Annual Global Healthcare Conference, Wednesday, February 15, 2017.     ...
Jan 11, 2017 04:38 pm ET
Intellia Therapeutics Joins Genomics England’s Industry Consortium
CAMBRIDGE, Mass. and LONDON, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics (NASDAQ:NTLA) has joined the Genomics England Genomics Expert Network for Enterprises (GENE) Consortium, as the first, dedicated genome editing company to participate in the 100,000 Genomes Project....
Dec 13, 2016 09:20 am ET
Intellia Therapeutics Names Graeme Bell Chief Financial Officer
CAMBRIDGE, Mass., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9 technology, has appointed Graeme Bell as its Chief Financial Officer. Mr. Bell succeeds Sapna Srivastava, Ph.D., who is transitioning to a senior advisory role within Intellia....
Dec 01, 2016 04:05 pm ET
Intellia Therapeutics Opens New Headquarters as Company Continues to Advance CRISPR/Cas9 Platform and Pipeline
- Positions Intellia for R&D growth and progress toward clinical studies -- Accommodates hiring plans to support pipeline of CRISPR/Cas9 based therapeutics -...
Nov 01, 2016 04:05 pm ET
Intellia Therapeutics Reports Financial Results for Third Quarter 2016
First company to report high in vivo editing data using CRISPR/Cas9 in animal modelsFurther validation of lipid nanoparticle delivery platformEnded quarter with $290.6 million in cash and cash equivalents CAMBRIDGE, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today reported results for the quarter ended September 30, 2016 and provided an update on recent highlights and upcoming events....
Oct 31, 2016 07:00 am ET
Intellia Therapeutics to Present at November Investor Healthcare Conferences
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that senior company leaders will present at key November investor healthcare conferences, including the 25th Annual Credit Suisse Healthcare Conference and the Jefferies 2016 London Healthcare Conference....
Oct 14, 2016 07:00 am ET
Intellia Therapeutics to Present Data at the European Society of Gene & Cell Therapy Congress
CAMBRIDGE, Mass., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that members of its scientific team will present new data at the European Society of Gene & Cell Therapy Congress (ESGCT) in Florence, Italy from October 18-21, 2016. Abstracts will be available online at esgct.eu on October 17, 2016....
Oct 05, 2016 07:00 am ET
Intellia Therapeutics to Present at Jefferies Gene Editing/Therapy Summit
CAMBRIDGE, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Medical Officer John Leonard, M.D., will participate in a panel discussion and present a company overview at the Jefferies Gene Editing/Therapy Summit on Tuesday, October 11, 2016.     ...
Sep 01, 2016 07:00 am ET
Intellia Therapeutics to Present at September Investor Healthcare Conferences
CAMBRIDGE, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that CEO and Founder Nessan Bermingham, Ph.D., will present at key September investor healthcare conferences, including the 2016 Wells Fargo Healthcare Conference, the Morgan Stanley Global Healthcare Conference and the Leerink Rare Disease & IO Roundtable Series....
Aug 18, 2016 09:36 pm ET
Intellia Therapeutics’ Preclinical Data Show Continued Progress in In Vivo Gene Editing With Systemic Lipid Nanoparticle Delivery of CRISPR/Cas9 components
CAMBRIDGE, Mass., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, presented preclinical data demonstrating in vivo gene editing using lipid nanoparticles (LNPs) to deliver CRISPR/Cas9. These data were presented at the 2016 meeting on Genome Engineering: The CRISPR/Cas Revolution, in Cold Spring Harbor, New York....
Aug 10, 2016 04:05 pm ET
Intellia Therapeutics to Present at 2016 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that CEO and Founder Nessan Bermingham, Ph.D., will present at the 2016 Wedbush PacGrow Healthcare Conference....
Aug 04, 2016 04:10 pm ET
Intellia Therapeutics Reports Financial Results for Second Quarter 2016
Advancing proprietary and partnered pipeline candidates with Novartis and RegeneronCash and cash equivalents of approximately $300.7 million to accelerate CRISPR/Cas9 platform and pipeline development  CAMBRIDGE, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today reported financial results and recent company highlights for the quarter ended June 30, 2016....
Jun 03, 2016 04:03 pm ET
Intellia Therapeutics to Present at the Jefferies 2016 Healthcare Conference and the International BIO Convention
CAMBRIDGE, Mass., June 03, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading gene editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at both the upcoming Jefferies 2016 Healthcare Conference and the 2016 International BIO Convention. Nessan Bermingham, PhD, Intellia’s Chief Executive Officer, will present on the company at Jefferies, and will participate in BIO’s next-generation Biotherapeutics panel session, “Gene Therapy or Gene Editing: Which one Will Change the Future of Medical Care?”...
May 11, 2016 04:05 pm ET
Intellia Therapeutics Announces Closing of Initial Public Offering
CAMBRIDGE, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced the closing of its initial public offering of 6,900,000 shares of its common stock at an initial public offering price of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares of common stock. Shares began trading on the NASDAQ Global Market on May 6, 2016....
May 11, 2016 10:00 am ET
May 05, 2016 07:02 pm ET
Intellia Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., May 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (”Intellia Therapeutics” or “Intellia”) a leading gene editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $18 per share. In addition, Intellia has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock at the initial public offering price, less the underwriting discount. Intellia’s comm...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.